KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to -$283.2 million.

  • Halozyme Therapeutics' Net Cash Flow fell 63631.07% to -$283.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $20.6 million, marking a year-over-year increase of 91630.95%. This contributed to the annual value of $20.6 million for FY2025, which is 91630.95% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Net Cash Flow is -$283.2 million, which was down 63631.07% from $357.8 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' Net Cash Flow peaked at $357.8 million during Q3 2025, and registered a low of -$373.0 million during Q4 2021.
  • Its 5-year average for Net Cash Flow is -$589100.0, with a median of $11.2 million in 2022.
  • In the last 5 years, Halozyme Therapeutics' Net Cash Flow soared by 239016.86% in 2021 and then crashed by 1548959.28% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Net Cash Flow stood at -$373.0 million in 2021, then skyrocketed by 123.34% to $87.0 million in 2022, then plummeted by 279.07% to -$155.9 million in 2023, then skyrocketed by 75.32% to -$38.5 million in 2024, then crashed by 636.31% to -$283.2 million in 2025.
  • Its last three reported values are -$283.2 million in Q4 2025, $357.8 million for Q3 2025, and -$114.5 million during Q2 2025.